Halberd Corp Letter to Shareholders
Halberd Corporation (OTC PINK: HALB) has recently shared a letter with its shareholders, detailing significant progress in its research and product development efforts, particularly highlighting its groundbreaking Tri-aX™ TBI nasal spray treatment.
Technical Progress and Strategic Developments
In the letter, Halberd addresses the concerns of investors who have noted a perceived quiet period within the company. However, Halberd reassures that this tranquility is a result of strategic planning and careful communication designed to safeguard its proprietary methods. As the company strengthens its partnerships, including its collaboration with Athena GTX under the leadership of CEO Mark Darrah, Halberd is dedicated to crafting effective commercialization and legal strategies for its developing products.
Tri-aX™ TBI Nasal Spray Treatment
This communication specifically emphasizes the Tri-aX™ TBI nasal spray treatment, which has recently attracted interest from military sectors. The treatment has undergone multiple preclinical studies at Mississippi State University (MSU), producing promising results that could transform the landscape of traumatic brain injury (TBI) treatment.
Research Collaborations and Funding Opportunities
Halberd's research at MSU has demonstrated that its proprietary formulation can significantly lower tissue biomarkers associated with neurological damage from TBI. This indicates that Tri-aX™ not only addresses immediate injury concerns but also tackles the long-term consequences of head trauma. Discussions with military researchers have initiated conversations about potential next steps in the research process.
Invited Proposal from the Department of Defense
On August 8, Halberd received notification from the Department of Defense (DoD) that its pre-proposal was chosen from a competitive pool, allowing the company to submit a full proposal for vital funding aimed at advancing research and developing methodologies for trauma treatment. This funding opportunity represents a significant milestone for Halberd, potentially providing up to $700,000 through the Congressionally Directed Medical Research Programs.
Future Directions and Research Goals
Halberd's upcoming application will focus on validating blood and brain biomarkers of injury to help assess the severity of TBI and monitor recovery patterns. By establishing a baseline for treatment effectiveness, the company hopes to showcase the impressive benefits of Tri-aX™ in practical applications.
Success Rates and Strategic Approaches
The letter highlights the broader context of success rates in medical research funding, noting that Halberd has achieved a commendable 66% success rate in proposals submitted in collaboration with its partners. The approaching proposal deadline emphasizes the urgency and significance of their efforts as they work to finalize their submission strategies.
Conclusion and Company Outlook
Halberd remains optimistic about its ongoing collaborations and the potential of Tri-aX™ to become a leader in TBI treatment. The company's dedication to transparency, strategic partnerships, and innovative advancements reflects its commitment to enhancing the lives of those affected by traumatic brain injuries.
For more information, please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC
Frequently Asked Questions
What is the focus of Halberd Corporation's recent developments?
Halberd Corporation is concentrating on its Tri-aX™ TBI nasal spray treatment for traumatic brain injuries and is working to establish partnerships for further research and funding opportunities.
How has the military shown interest in Halberd's products?
The Department of Defense selected Halberd's pre-proposal for TBI treatment, inviting the company to submit a full application for funding, which indicates significant military interest.
What is the expected funding amount Halberd might receive?
Halberd could receive up to $700,000 in funding as part of the Department of Defense’s Congressionally Directed Medical Research Programs.
How does Tri-aX™ work in treating traumatic brain injuries?
Tri-aX™ is designed to reduce biomarkers of tissue damage and enhance recovery outcomes following a traumatic brain injury, utilizing its innovative nasal spray formulation.
What strategic measures is Halberd taking for its proprietary products?
Halberd is focusing on forming strategic partnerships, maintaining confidentiality around its proprietary methodologies, and carefully planning communication strategies to optimize product development.
